UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 12, 2016

 

 

 

MEDNAX, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Florida   001-12111   26-3667538

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

1301 Concord Terrace

Sunrise, Florida 33323

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code (954) 384-0175

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 12, 2016, MEDNAX, Inc., a Florida corporation (the “Company”), held its 2016 Annual Shareholders’ Meeting (the “Annual Meeting”). Of the 92,913,265 shares of common stock outstanding and entitled to vote, 80,145,252 shares were represented, constituting a quorum. The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

Proposal 1: All of the Board’s nominees for Director were elected to serve until the Company’s 2017 Annual Shareholders’ Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below:

 

Name    For    Withheld   

Broker

Non-Vote

       

Cesar L. Alvarez

   63,339,464    13,069,681    3,736,107
       

Karey D. Barker

   76,347,561    61,584    3,736,107
       

Waldemar A. Carlo, M.D.

   73,410,257    2,998,888    3,736,107
       

Michael B. Fernandez

   71,064,194    5,344,951    3,736,107
       

Paul G. Gabos

   74,679,529    1,729,616    3,736,107
       

Pascal J. Goldschmidt, M.D.

   76,171,097    238,048    3,736,107
       

Manuel Kadre

   76,178,992    230,153    3,736,107
       

Roger J. Medel, M.D.

   75,114,052    1,295,093    3,736,107
       

Donna E. Shalala, Ph.D.

   76,285,637    123,508    3,736,107
       

Enrique J. Sosa, Ph.D.

   74,974,250    1,434,895    3,736,107

Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered certified public accounting firm for the 2016 fiscal year was ratified by the shareholders, by the votes set forth in the table below:

 

For    Against    Abstained   

Broker

Non-Vote

       

78,307,180

   1,813,439    24,633    0


Proposal 3: The shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, by the votes set forth in the table below:

 

For    Against    Abstained   

Broker

Non-Vote

       

70,029,836

   6,333,819    45,490    3,736,107


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      MEDNAX, INC.
Date:   May 13, 2016     By:  

/s/ Vivian Lopez-Blanco

       

Vivian Lopez-Blanco

Chief Financial Officer